Table 5.

New antibiotics for CAP treatment

	Reported severity of patients included in trials	Dose and posology
Ceftobiprole	All hospitalized patients; PORT risk class V: 1.7% of population studya	500 mg, iv, 8/8 h, 2 h infusion
Ceftaroline	Only PORT risk class III or IV (not admitted to ICU on recruitment)	600 mg, iv, 12/12 h
Omadacycline	PORT risk class II, III or IV	100 mg, iv, 12/12 h for 2 doses, followed by 100 mg, iv, daily, or 300 mg, orally, daily
Delafloxacin	PORT risk class II–V, excluding patients admitted to ICU (not yet published)	300 mg, iv, 12/12 h or 450 mg, orally, 12/12 h
Solithromycin	PORT risk class II–IV in both trials	800 mg orally (or 400 mg iv), on the first day followed by 400 mg orally or iv, daily
Lefamulin	(a) PORT risk class ≥ III, excluding mechanically ventilated; in PORT class III–V, not mechanically ventilated; (b) PORT risk class II–IV	150 mg, iv, 12/12 h or 600 mg, orally, 12/12 h

PORT Pneumonia Patient Outcomes Research Team, iv intravenous

^aCeftobiprole arm 1.2% (4/314) and comparator arm 2.2% (7/329)